Literature DB >> 10915907

Neurotrophic effect of basic fibroblast growth factor is mediated by the p42/p44 mitogen-activated protein kinase cascade in cultured rat cortical neurons.

K Abe1, H Saito.   

Abstract

Basic fibroblast growth factor (bFGF) has been reported to support the survival of brain neurons. In the present study, we investigated whether the neurotrophic effect of bFGF is mediated by the mitogen-activated protein kinase (MAPK) cascade in cultured rat cerebral cortical neurons. Recombinant human bFGF (0.1-10 ng/ml) induced phosphorylation of p44/42 MAPK (ERK1/2) in a concentration- and time-dependent manner. bFGF-induced ERK1/2 phosphorylation and promotion of neuronal survival were both blocked by U0126 and PD98059, inhibitors of the MAPK-activating enzyme MEK. These results suggest that the MEK/ERK signal transduction cascade is involved in the neurotrophic effect of bFGF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915907     DOI: 10.1016/s0165-3806(00)00054-7

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  13 in total

1.  A sensory neuron subpopulation with unique sequential survival dependence on nerve growth factor and basic fibroblast growth factor during development.

Authors:  C G Acosta; A R Fábrega; D H Mascó; H S López
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

2.  Targeted induction of differentiation of human bone mesenchymal stem cells into neuron-like cells.

Authors:  Zhaohui Cheng; Qixin Zheng; Weici Wang; Xiaodong Guo; Yongchao Wu; Jin Zheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

3.  Basic fibroblast growth factor prevents the memory impairment induced by gastrin-releasing peptide receptor antagonism in area CA1 of the rat hippocampus.

Authors:  Thales Preissler; Tatiana Luft; Flávio Kapczinski; João Quevedo; Gilberto Schwartsmann; Rafael Roesler
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

Review 4.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

Review 5.  Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.

Authors:  Hyongbum Kim; Julie J Kim; Young-sup Yoon
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2012-06       Impact factor: 2.895

6.  Acute endotoxemia prolongs the survival of rat lung neutrophils in response to 12-O-tetradecanoyl-phorbol 13-acetate.

Authors:  Vasanthi R Sunil; Agnieszka J Connor; Natasha Lavnikova; Carol R Gardner; Jeffrey D Laskin; Debra L Laskin
Journal:  J Cell Physiol       Date:  2002-03       Impact factor: 6.384

7.  Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy.

Authors:  Jin-Ok Jeong; Mee-Ohk Kim; Hyongbum Kim; Min-Young Lee; Sung-Whan Kim; Masaaki Ii; Jung-uek Lee; Jiyoon Lee; Yong Jin Choi; Hyun-Jai Cho; Namho Lee; Marcy Silver; Andrea Wecker; Dong-Wook Kim; Young-sup Yoon
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

8.  The increase in retinal cells proliferation induced by FGF2 is mediated by tyrosine and PI3 kinases.

Authors:  Carla Valéria Vieira Guilarducci-Ferraz; Gustavo Mataruna da Silva; Patrícia Maria Mendonça Torres; Aline Araújo Dos Santos; Elizabeth Giestal de Araújo
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

9.  Involvement of MAPK/ERK kinase-ERK pathway in exogenous bFGF-induced Egr-1 binding activity enhancement in anoxia-reoxygenation injured astrocytes.

Authors:  Ying Liu; Jin-Biao Lu; Qi Chen; Zhu-Rong Ye
Journal:  Neurosci Bull       Date:  2007-07       Impact factor: 5.203

10.  Degeneration of axotomized projection neurons in the rat dLGN: temporal progression of events and their mitigation by a single administration of FGF2.

Authors:  Michael L Hendrickson; Changying Ling; Ronald E Kalil
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.